Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Arcturus Therapeutics Holdings Inc. ARCT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$22.50
+159.2%

Arcturus Therapeutics Holdings Inc. (ARCT) is a Biotechnology company in the Healthcare sector, currently trading at $8.68. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ARCT = $23 (+159.2% upside).

Valuation: ARCT trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25).

Financials: revenue is $67M, -29%/yr average growth. Net income is $66M (loss), growing at -190.5%/yr. Net profit margin is -97.9% (negative). Gross margin is 95.5% (+65 pp trend).

Balance sheet: total debt is $25M against $214M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 6.64 (strong liquidity). Debt-to-assets is 9.2%. Total assets: $271M.

Analyst outlook: 12 / 21 analysts rate ARCT as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$22.50
▲ 159.22% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Arcturus Therapeutics Holdings Inc., the average price target is $22.50, with a high forecast of $25.00, and a low forecast of $20.00.
Highest Price Target
$25.00
Average Price Target
$22.50
Lowest Price Target
$20.00

ARCT SharesGrow Score Overview

52/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARCT

✓
VALUE Pass
100/100
ARCT trades at a trailing Price-to-Earnings (P/E) of -3.4 (S&P 500 average ~25). Forward PEG -0.89 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $23, implying +165% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ARCT: -29%/yr revenue is, -190.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ARCT: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet ARCT: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 6.64 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
ARCT: Gross margin is 95.5% (+65 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 12 / 21 analysts rate ARCT as buy (57%). Analyst consensus target is $23 (+165% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ARCT: Net profit margin is -97.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.85-24.17
Volume332.2K
Avg Volume (30D)529.47K
Market Cap$246.71M
Beta (1Y)2.44
Share Statistics
EPS (TTM)-2.40
Shares Outstanding$27.39M
IPO Date2013-05-22
Employees174
CEOJoseph E. Payne
Financial Highlights & Ratios
Revenue (TTM)$67.22M
Gross Profit$64.2M
EBITDA$-71.93M
Net Income$-65.78M
Operating Income$-74.96M
Total Cash$230.91M
Total Debt$25M
Net Debt$-205.91M
Total Assets$271.15M
Price / Earnings (P/E)-3.6
Price / Sales (P/S)3.67
Analyst Forecast
1Y Price Target$22.50
Target High$25.00
Target Low$20.00
Upside+159.2%
Rating ConsensusBuy
Analysts Covering21
Buy 57% Hold 24% Sell 19%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS03969T1097

Price Chart

Track all markets on TradingView
ARCT
Arcturus Therapeutics Holdings Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
5.85 52WK RANGE 24.17

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
 CRSP
CRSP
CRISPR Therapeutics AG
$56.86
+3.70%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 BEAM
BEAM
Beam Therapeutics Inc.
$30.30
+0.40%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message